Document Detail

Rosuvastatin Changes Cytokine Expressions in Ischemic Territory and Preserves Heart Function After Acute Myocardial Infarction in Rats.
MedLine Citation:
PMID:  23139358     Owner:  NLM     Status:  Publisher    
Aim:To investigate the mechanism of rosuvastatin in preserving cardiac function after acute myocardial infarction (AMI) in a rat model. METHODS: Sprague-Dawley rats were randomized to receive either rosuvastatin (5 mg/kg every day) or placebo (0.5% CMC-Na), respectively, by daily gavage from 7 days before AMI. Acute myocardial infarction (AMI) model was induced by left anterior descending coronary artery ligation through a lateral thoracotomy in rats. The expressions of stromal-cell-derived factor 1 (SDF-1), chemokine motif CXC receptor 4 (CXCR-4), vascular endothelial growth factor (VEGF), and intercellular adhesion molecule 1 (ICAM-1) in peri-infarction region and nonischemic region at different time points were determined by the Western blot analysis. Immunohistochemistry analysis was performed on the 28th day after AMI to investigate the accumulation of CD90+, CD133+, and c-kit+ progenitor cells in the peri-infarction region. Masson staining and echocardiograph were performed to evaluate the left ventricular remodeling and postinfarction cardiac function 4 weeks after AMI. RESULTS: Western blot analysis showed that rosuvastatin could change the cytokine expressions in the peri-infarction region by upregulating the SDF-1 expression and downregulating the expressions of CXCR-4, ICAM-1, and VEGF in 4 to 14 days after AMI. Immunohistochemistry analysis showed that rosuvastatin treatment was associated with increased accumulation of CD90+, CD133+, and c-kit+ progenitor cells in the peri-infarction region. Masson staining and echocardiograph confirmed that rosuvastatin could attenuate left ventricular remodeling and improve postinfarction systolic function. CONCLUSION: The data suggest that rosuvastatin can protect the heart from ischemic injury and preserve the cardiac function in rats in vivo. The changing expressions of SDF-1, CXCR-4, ICAM-1, and VEGF, and the accumulation of progenitor cells were involved in this process.
Xinying Hu; Aijun Sun; Xinxing Xie; Zheyong Huang; Jianguo Jia; Ruiming Yao; Junbo Ge
Related Documents :
20723638 - A novel percutaneous coronary intervention risk score to predict one-year mortality.
24826278 - From recurrent syncope to sudden cardiac death: clinical characteristics in a chinese p...
23736098 - Noncompaction in mitochondrial myopathy: visible on microscopy but absent on macroscopi...
24529748 - Silent myocardial ischemia detected by single photon emission computed tomography (spec...
11832088 - Right ventricular function of patients with septic shock: clinical significance.
24584738 - The importance of purkinje activation in long duration ventricular fibrillation.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-8
Journal Detail:
Title:  Journal of cardiovascular pharmacology and therapeutics     Volume:  -     ISSN:  1940-4034     ISO Abbreviation:  J. Cardiovasc. Pharmacol. Ther.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9602617     Medline TA:  J Cardiovasc Pharmacol Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
1Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Insights into the molecular mechanism for type 2 diabetes susceptibility at the KCNQ1 locus from tem...
Next Document:  Intensive-Dose Atorvastatin Regimen Halts Progression of Atherosclerotic Plaques in New-onset Unstab...